linjc16/ctgov huggingface dataset:
Effect of Timing of a Post-exercise Oral Glucose Tolerance Test on Glycaemic Control.

Study Overview
=================
Brief Summary
-----------------
Postprandial glycaemic control is an important risk factor for the development of type 2 diabetes, cardiovascular disease and all-cause mortality. Previous research has demonstrated that exercise performed in the postprandial state paradoxically results in a deterioration in glucose tolerance in the immediate post-exercise period (Gonzalez et a. 2013; Gonzalez and Stevenson 2013). This study aims to assess the timecourse of this post-exercise effect.

Official Title
-----------------
Effect of Timing of a Post-exercise Oral Glucose Tolerance Test on Glycaemic Control.

Conditions
-----------------
Area Under Curve [N06.850.520.830.200]

Intervention / Treatment
-----------------
* Behavioral: Exercise
* Behavioral: Rest
* Behavioral: Delay


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal weight (18-25 kg/m2) Physically active (>or= 3 times per week) Male Exclusion Criteria: Contraindications to exercise Food intolerances Food allergies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Rest<br>Breakfast followed by a rest period prior to OGTT. | Behavioral: Rest<br>* Rest for 30 min<br>|
| Experimental: Exercise-immediate<br>Breakfast followed by exercise and an immediate OGTT | Behavioral: Exercise<br>* Exercise at 55% of maximum power output for 30 min.<br>|
| Experimental: Exercise-delay<br>Breakfast followed by exercise and a delayed (1 h) OGTT. | Behavioral: Exercise<br>* Exercise at 55% of maximum power output for 30 min.<br>Behavioral: Delay<br>* Delay between exercise and OGTT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postprandial glucose concentration area under the curve | Blood glucose concentrations will be sampled every 15 min following an oral glucose tolerance test. | 90 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postprandial insulin concentration area under the curve | Insulin concentrations will be determine every 15 min following an oral glucose tolerance test. | 90 min |
Prior Abdominal Surgery: A Potential Risk Factor for Colonic Diverticulosis or Diverticulitis

Study Overview
=================
Brief Summary
-----------------
Background & Aims: Abnormal colonic pressure profiles have been associated with an increased risk of colonic diverticulosis. A surgical history is a known risk factor for abdominal adhesions, and these may lead to increased intraluminal colonic pressure. We assessed whether previous abdominal surgery is associated with colonic diverticulosis or diverticulitis. Methods: The investigators analyzed data from a prospective study of patients undergoing colonoscopy for different indications from 2020 through 2021. Patients completed a structured questionnaire concerning previous abdominal surgeries, dietary and lifestyle exposures including smoking and alcohol use, and co-morbidities.

Official Title
-----------------
Prior Abdominal Surgery: A Potential Risk Factor for Colonic Diverticulosis or Diverticulitis

Conditions
-----------------
Diverticulosis, Colonic, Abdominal Adhesion, Diverticulitis

Intervention / Treatment
-----------------
* Other: comparison


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients > 18 years old who are going through colonoscopy in shamir medical center for any reason Exclusion Criteria: inadequate preparation (Boston Bowel Preparation Quality Scale <6); previous colonic resection based on history and colonoscopy; previous colon cancer.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: comparison|abdominal surgery as a risk factor for diverticulosis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between prior abdominal surgery and the development of diverticulosis | the investigators are willing to see if prior abdominal surgery raise the patient's risk of developing future diverticulosis. The investigators use questionere to collect data from patients. The final measurements will be calculatrd with spss software | in the end of the study (estimated in 1 year) |
Efficacy and Safety of VA106483 in Elderly Males

Study Overview
=================
Brief Summary
-----------------
A double blind, placebo-controlled, dose ranging study in males over the age of 65, who have a history of nocturia. The study will investigate pharmacodynamic outcomes (urine volumes and osmolality, circulating coagulation factors and haemodynamics) and pharmacokinetics, of both single and multiple oral doses of VA106483 at three dose levels, under conditions of controlled hydration.

Detailed Description
-----------------
VA106483 is a selective vasopressin V2 receptor agonist which is currently under development for the treatment of nocturia in males. This study examines the pharmacological action of VA106483 on markers of clinical efficacy (urine volumes and osmolality) and safety markers (coagulation factors and haemodynamics). The study will also assess the pharmacokinetics in the study population. The study design includes both cross-over and parallel phases so that pharmacodynamic and pharmacokinetic parameters can be assessed following both single and repeat dosing. Three dose levels will be given.

Official Title
-----------------
A Double-blind, Placebo-controlled Dose Response Study to Investigate Pharmacodynamics and Pharmacokinetics of Single and Repeated Oral Doses of VA106483 in Elderly Male Subjects

Conditions
-----------------
Nocturia

Intervention / Treatment
-----------------
* Drug: VA106483
* Drug: Sugar pill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males 65 years and above with history of nocturia Exclusion Criteria: Any clinically significant concomitant medical disease, condition or abnormal laboratory test result Participation in any other clinical study within 30 days Intake of non-prescription medication within 14 days

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Sugar pill<br> | Drug: Sugar pill<br> <br> |
| Experimental: VA106483 2 mg<br> | Drug: VA106483<br> <br> |
| Experimental: VA106483 4 mg<br> | Drug: VA106483<br> <br> |
| Experimental: VA106483 8 mg<br> | Drug: VA106483<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacodynamic profile of VA106483 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic profile of VA106483 |  |  | 
| Safety and tolerability of VA106483 |  |  |
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the use of a sequential high dose chemotherapy is more effective than conventional dose (i.e. 4 cycles of cisplatin, etoposide, and bleomycin [PEB]) in patients with metastatic poor prognosis germ cell tumors.

Official Title
-----------------
Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors

Conditions
-----------------
Testicular Neoplasms, Germ Cell Tumors

Intervention / Treatment
-----------------
* Drug: Cyclophosphamide
* Drug: Etoposide
* Drug: Cisplatin
* Drug: Bleomycin
* Drug: Carboplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical or Histological diagnosis of germ cell tumors Metastatic disease Poor prognostic category according to the International Germ Cell Collaborative Group (IGCCCG) classification No prior chemotherapy for metastatic disease Exclusion Criteria: Unwillingness to accomplish the study procedures Any existing co-morbidity that could limit the administration of high dose chemotherapy Any psychiatric disorder that could impact on the study compliance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High dose chemotherapy<br>Characterized by the following sequence: High dose cyclophosphamide (7 grams/squared meter) x 1 cycle 2 cycles of high-dose etoposide and cisplatin 1 cycle of high dose carboplatin (Area Under the Curve 27) with stem cell rescue | Drug: Cyclophosphamide<br> <br> Drug: Etoposide<br> <br> Drug: Cisplatin<br> <br> Drug: Carboplatin<br>* High dose carboplatin<br>|
| Active Comparator: Conventional dose chemotherapy<br>Cisplatin, Etoposide, and Bleomycin (PEB) x 4 cycles | Drug: Etoposide<br> <br> Drug: Cisplatin<br> <br> Drug: Bleomycin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of disease progression confirmed by computed tomography (CT) scan and/or serum tumor markers. |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 5 years |
The Association of Endothelial Dysfunction and Cardiac Allograft Vasculopathy

Study Overview
=================
Brief Summary
-----------------
Progressive cardiac allograft vasculopathy (CAV) is a serious complication in long-term survivors after heart transplantation. Therefore, we hypothesize that CAV is a diffuse and progressive process, and endothelial function may play an important role in predicting clinical outcome after heart transplantation. Therefore, this single-blinded study is designed to evaluate endothelial function, microvascular flow response and morphology of coronary artery in cardiac allografts, The simultaneous use of IVUS and Doppler wire instrumentation in different pharmacological stress; Tl-201 SPECT (dipyridamole stress/rest); to evaluate the correlation of endothelial function, coronary morphology change and Tl-201 dipyridamole stress myocardial perfusion image.

Conditions
-----------------
Heart Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Heart transplant receipients who undergoing the coronary angiographic follow-up as standard protocols. Exclusion Criteria: Acute illness conditions including infection, congestive heart failure (NYHA Fc III, IV), etc. Coronary angiographic finding: coronary stenosis>30% (as grade III, IV by Klauss V et al, Am J Cardiol 1995; 76:463-6). Creatinine >3.0 mg/dl

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
1. Transplant vasculopathy, 2. Endothelial dysfunction, 3. Myocardial perfusion imaging, 4. Intravascular vascular ultrasound
Asthma Control-A Patient Follow up Programme Maintenance and Reliever Therapy in a Single Inhaler

Study Overview
=================
Brief Summary
-----------------
To investigate the change in patient's asthma symptom control using ACQ scores after 4 to 6 weeks of Symbicort Turbuhaler (budesonide/ formoterol) in SMART approach.

Official Title
-----------------
A Patient Follow-up Program to Assess Asthma Control in Patients Using Symbicort® as Maintenance and Relief Therapy in a Single Inhaler (Symbicort® SMART: Budesonide/Formoterol 160/4.5 Mcg, 1 or 2 Inhalations x 2 Times Plus Additional Inhalations as Needed)

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asthma patients from both sexes, age 18 or older Have already been on Symbicort SMART treatment Willing to give written informed consents to participate in the program. Exclusion Criteria: Patients who are not willing to give written informed consent Patients in emergency care for asthma at ICUs or COPD patients are excluded from the program.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Symbicort, NIS
Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

Study Overview
=================
Brief Summary
-----------------
Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the investigational MOA-728 regimen than with a placebo regimen.

Official Title
-----------------
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus.

Conditions
-----------------
Post Operative Bowel Dysfunction

Intervention / Treatment
-----------------
* Drug: Methylnaltrexone (MOA-728)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Must be scheduled for a segmental colectomy via open laparotomy with general anesthesia Subjects with history of inflammatory bowel disease are eligible as long as the disease is not currently active and all other criteria are met Subjects must meet the American Society of Anesthesiologists physical status I, II or III Exclusion: Subjects who are scheduled for laparoscopic surgery for the segmental colectomy Subjects with a recent history (<1 year prior to randomization) of abdominal radiation therapy; Subjects with a history of small bowel obstruction, known or suspected bowel adhesions (other than minor, clinically nonsignificant adhesions) Subjects undergoing operations resulting in gastrointestinal ostomies, or who require use of post operative nonsteroidal anti-inflammatory drugs (NSAIDs)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Methylnaltrexone (MOA-728)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the MOA-728 regimen than with a placebo regimen. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bowel
PROSTACOX : Metastatic Prostate Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.

Detailed Description
-----------------
Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation

Official Title
-----------------
Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer

Conditions
-----------------
Metastatic Prostate Cancer

Intervention / Treatment
-----------------
* Drug: docetaxel and celecoxib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: metastatic prostate cancer ASCO progression criteria Exclusion Criteria: other prostate chemotherapy
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: docetaxel and celecoxib|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis

Study Overview
=================
Brief Summary
-----------------
Neutrophils play a central role in innate immunity and are rapidly recruited to sites of infection and injury. Neutrophil apoptosis and necroptosis are essential for the inflammatory.This study is designed to investigate the cells and the molecular mechanisms of neutrophil necroptosis and apoptosis.

Detailed Description
-----------------
Necrosis has recently been demonstrated to be programmatic and energy comsuming, a process termed necroptosis. In this project, the investigators aim to investigate the mechanisms and the effects ofneutrophil necroptosis and apoptosis: 1. to investigate the cells and the molecular mechanisms that induce neutrophil necroptosis or delay apoptosis, mainly focusing on the roles of HMGB-1,TNF-α and LPS, 2. to illustrate the effects of some molecules such as TLR, TNFR, RIP1/RIP3, Caspase8, ATP and ROS in the process of sigal transduction and membrane damage during necroptosis or apoptosis , 3. to identify the similarities and differences between traditional necrosis and necroptosis in the aspects of morphologigical changes and inflammatory cytokine release, 4. to find out the effects and mechanisms of neutrophil necroptosis or apoptosis in a rheumatoid arthritis mouse model and the therapeutic effect of blocking one or several pathways in the pathogenesis of rheumatoid arthritis. This study will not only unravel the mechanisms of neutrophil necroptosis and apoptosis, elucidate its roles and significances in inflammation and infection, but also shed new light on anti-inflammatory and anti-infection therapy.

Official Title
-----------------
Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Volunteers age 18-65. Exclusion Criteria: Don't agree with informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The apopotosis and necroptosis of Neutrophils |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
necroptosis, Neutrophils, apoptosis
Allergen Immunotherapy in Allergic Patients

Study Overview
=================
Brief Summary
-----------------
Our aim was to evaluate the effectiveness of subcutaneous allergen immunotherapy with the symptom scores (RSS), visual analog scale (VAS) and medication scores (MS) and the impact on quality of life with rhinoconjunctivitis quality of life questionnaire (RQLQ) in allergic rhinitis patients sensitized to different allergens. Also the development of new sensitizations and asthma during the immunotherapy were determined.

Detailed Description
-----------------
Allergic rhinitis patients sensitized to at least one common aero-allergen who completed a three or five year period of allergen immunotherapy in our outpatient clinic between 2002-2013 were enrolled in the study and patients with allergic rhinitis who received only medical treatment were chosen as the control group. Patients were separated in two groups according to sensitization patterns including pollens or house dust mites. All patients were evaluated before immunotherapy, in the first and the fifth years of treatment and two years after the treatment.

Official Title
-----------------
Long Term Follow up in Patients Using Immunotherapy: Efficacy and Impact on Quality of Life

Conditions
-----------------
Allergic Rhinitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: allergic rhinitis/asthma Exclusion Criteria: pregnancy, malignity, autoimmunity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The improvent of quality of life |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
immunotherapy, house dust mites, pollens, allergic rhinitis